Summary
Etoxadrol is a dioxolane NMDA antagonist developed as a dissociative anesthetic; unlike arylcyclohexylamines (PCP/ketamine), it features a 1,3-dioxolane piperidine scaffold. Clinical work shows IV 0.75 mg/kg yields anesthesia averaging 26 minutes (14-53 minutes) with active airway reflexes but raised heart rate/blood pressure and tachypnea. Prominent post-dose phenomena include alternating nystagmus lasting hours and vivid dream-like states; approximately 20% of patients reported unpleasant or threatening dreams persisting up to 24 hours. One overdose case at 4.65 mg/kg caused catalepsy, amnesia, and analgesia lasting 6 days. Binding studies place etoxadrol as a high-affinity PCP-site channel blocker at NMDA receptors (Ki = 107 nM), explaining PCP-like behavioral effects and animal self-administration.
Dose Information
Onset, Duration & After-effects
| ROA | Offset | After Effects |
|---|---|---|
| Intravenous (Clinical Use Only) | 15-60 min | 18-24 hrs |
Tolerance
Effects
- Analgesia
- Stimulation
- Physical euphoria
- Stamina enhancement
- Creativity enhancement
- Nystagmus
- Tachycardia
- Nausea
- Numbness
- Loss of balance
- Cognitive euphoria
- Amnesia
- Depersonalization
- Confusion
- Anxiety
- Derealization
- Motor control loss
- Memory suppression
- Dissociation
- Time distortion
- Perception of bodily lightness
- Bodily control enhancement
- Visual acuity enhancement
- Tactile suppression
- Derealization
- Dream-like imagery
- After images
- Drifting
- Environmental cubism
- Environmental orbism